Myeloid Neoplasia

A collection of features and news articles published in ASH Clinical News related to myeloid neoplasia.

Demystifying Epigenetics in Hematology

In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...

European Commission Approves CPX-351 for Two Types of AML

The European Commission (EC) has approved CPX-351 for the treatment of adult patients with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid...

Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...

In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...

Next Steps After TKIs for Patient With Chronic-Phase CML?

Here’s how readers responded to a You Make the Call question about the next steps after TKIs for patient with chronic-phase chronic myeloid leukemia. Disclaimer:...

FDA Approves Ivosidenib for Previously Treated, IDH1-Mutated AML

The FDA approved ivosidenib, a small-molecule IDH1 inhibitor, for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and an...

Next Steps After TKIs for Patient With Chronic-Phase CML?

This month, Michael Deininger, MD, PhD, discusses treatment for a patient with chronic-phase chronic myeloid leukemia (CML) whose BCR/ABL transcript levels are rising. And don't...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology Association, all four evaluable patients with TP53-mutant myelodysplastic syndromes...
WIB_icon

Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML

Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...

Somatic Mutations and Co-Mutations Predict AML Risk in Women

According to results from a deep-sequencing analysis published in Nature Medicine, women with mutations of the TP53 and IDH genes in the absence of...

FDA Places Partial Clinical Hold on AML and MDS Trial

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on a phase I/II trial of OXi4503, a vascular disrupting agent...

SHARE